Brought to you by 
Medtronic, Genzyme form cardiac repair JV
03 Jun 2004
Executive Summary
Medtronic is forming a joint venture with Genzyme Corp. called MG Biotherapeutics which will be responsible for developing new cardiovascular disease therapeutics.
Deal Industry
- Medical Devices
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
-
Drug Delivery
-
Medical Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
-
Surgical Equipment & Devices
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Joint Venture
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Medtronic, Genzyme form cardiac repair JV
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice